Leronlimab
Solid Tumor, Adult
Phase II
Completed
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
Jun 10, 2020
―
Leronlimab
Coronavirus Disease 2019
Phase II
Completed
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Apr 13, 2020
―
Pro 140
HIV-1-Infection
Phase II/III
Completed
PRO 140 in Treatment-Experienced HIV-1 Subjects
Apr 02, 2019
―
350 Mg Leronlimab, 525 Mg Leronlimab, 700 Mg Leronlimab, Auc 5 Carboplatin, Maximum Tolerated Dose Of Leronlimab
Triple Negative Breast Neoplasms
Phase I/II
Terminated
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Feb 05, 2019
―
Pro 140
Hiv
Phase II/III
Completed
Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection
Jul 13, 2016
―
Pro 140 350Mg Weekly Subcutaneous Injection.
Hiv, Human Immunodeficiency Virus
Phase II
Terminated
An Extension of Protocol PRO 140_CD01 Study
Jan 30, 2015
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does CytoDyn (296) have in its pipeline
296 is currently developing the following drugs: 350 Mg Leronlimab, 700 Mg Leronlimab, Leronlimab, Leronlimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.